Breakthrough Could Ease Chronic Constipation

Here’s some hopeful news for people living with Parkinson’s disease: a breakthrough from Australian scientists might lead to better treatment for one of the most frustrating and poorly managed symptoms — chronic constipation. It might not be the most glamorous topic, but constipation affects up to 90% of people with Parkinson’s and seriously impacts quality of life. Until now, no one’s really nailed why it happens — or how to fix it properly. That might be about to change, thanks to a discovery involving a little hormone called ghrelin, often nicknamed the “hunger hormone”. The surprising role of ghrelin Researchers at the University of Queensland (UQ) have found that ghrelin’s receptor — essentially the part of the body that receives its signal — plays a key role in helping us go to the loo. More specifically, it supports dopamine (a “feel good” brain chemical) in controlling the part of the spinal cord that manages bowel movements. In people with Parkinson’s, it turns out that the dopamine system in the spine can start to misfire — not just the brain. And that, researchers say, may explain why constipation is so common. What’s exciting is that this misfiring might be “fixed” by targeting the ghrelin receptor. Why it matters This is a big deal. Constipation in Parkinson’s isn’t just a nuisance — it can be exhausting, painful, and embarrassing. Worse still, it’s currently hard to treat. Current medications don’t do much, and advice often boils down to fibre, fluids, and hope. This new research could change that, offering the possibility of more targeted, effective treatments that actually address the root of the problem — not just the symptoms. What’s next? The UQ team is now exploring whether drugs that activate the ghrelin receptor might help people with Parkinson’s regain normal bowel control. Their research is considered so promising that the U.S. Department of Defense has awarded them $3 million to continue the work. In the words of lead researcher Associate Professor Sebastian Furness: “This discovery might allow us to substantially improve the lives of people living with Parkinson's.” A fresh approach This new theory — that ghrelin and dopamine need to work together in the spinal cord to keep things moving — could reshape how we understand and treat one of Parkinson’s most under-discussed but deeply disruptive symptoms. If successful, the ghrelin-based treatments might do more than ease discomfort — they could restore confidence, independence, and quality of life.